Literature DB >> 15121704

Quantification of tumour response to radiotherapy.

Q Y Gong1, P R Eldridge, A R Brodbelt, M García-Fiñana, A Zaman, B Jones, N Roberts.   

Abstract

In 1979, the World Health Organization (WHO) established criteria based on tumour volume change for classifying response to therapy as (i) progressive disease (PD), (ii) partial recovery (PR), and (iii) no change (NC). Typically, the tumour volume is reported from diameter measurements, using the calliper method. Alternatively, the Cavalieri method provides unbiased volume estimates of any structure without assumptions about its shape. In this study, we applied the Cavalieri method in combination with point counting to investigate the changes in tumour volume in four patients with high grade glioma, using 3D MRI. In particular, the volume of tumour within the enhancement boundary, the enhancing abnormality (EA), was estimated from T(1) weighted images, and the volume of the non-enhancing abnormality, (NEA) enhancing abnormality, was estimated from T(2) relaxation time and magnetic transfer ratio tissue characterization maps. We compared changes in tumour volume estimated by the Cavalieri method with those obtained using the calliper method. Absolute tumour volume differed significantly between the two methods. Analysis of relative change in tumour volume, based on the WHO criteria, provided a different classification using the calliper and Cavalieri methods. The benefit of the Cavalieri method over the calliper method in the estimation of tumour volume is justified by the following factors. First, Cavalieri volume estimates are mathematically unbiased. Second, the Cavalieri method is highly efficient under an appropriate sampling density (i.e. EA volume estimates can be obtained with a coefficient of error no higher than 5% in 2-3 min). Third, the source of variation of the volume estimates due to disagreements between observers, and within observer, is much greater in the positioning of the calliper diameters than in the identification of the tumour boundaries when applying the Cavalieri method. Additionally, the error prediction formula, available to estimate the coefficient of error of Cavalieri volume estimates from the data, allows us to establish more precise classification criteria against which to identify potentially clinical significant changes in tumour volume.

Entities:  

Mesh:

Year:  2004        PMID: 15121704     DOI: 10.1259/bjr/85294528

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  5 in total

Review 1.  Efficient quantitative morphological phenotyping of genetically altered organisms using stereology.

Authors:  John Milton Lucocq
Journal:  Transgenic Res       Date:  2006-11-14       Impact factor: 2.788

2.  Tumor recovery by angiogenic switch from sprouting to intussusceptive angiogenesis after treatment with PTK787/ZK222584 or ionizing radiation.

Authors:  Ruslan Hlushchuk; Oliver Riesterer; Oliver Baum; Jeanette Wood; Guenther Gruber; Martin Pruschy; Valentin Djonov
Journal:  Am J Pathol       Date:  2008-09-11       Impact factor: 4.307

3.  MR imaging of high-grade brain tumors using endogenous protein and peptide-based contrast.

Authors:  Zhibo Wen; Shuguang Hu; Fanheng Huang; Xianlong Wang; Linglang Guo; Xianyue Quan; Silun Wang; Jinyuan Zhou
Journal:  Neuroimage       Date:  2010-02-24       Impact factor: 6.556

4.  Assessment of Glioma Response to Radiotherapy Using Multiple MRI Biomarkers with Manual and Semiautomated Segmentation Algorithms.

Authors:  Yang Yu; Dong-Hoon Lee; Shin-Lei Peng; Kai Zhang; Yi Zhang; Shanshan Jiang; Xuna Zhao; Hye-Young Heo; Xiangyang Wang; Min Chen; Hanzhang Lu; Haiyun Li; Jinyuan Zhou
Journal:  J Neuroimaging       Date:  2016-04-29       Impact factor: 2.486

5.  Prediction of glioblastoma multiform response to bevacizumab treatment using multi-parametric MRI.

Authors:  Mohammad Najafi; Hamid Soltanian-Zadeh; Kourosh Jafari-Khouzani; Lisa Scarpace; Tom Mikkelsen
Journal:  PLoS One       Date:  2012-01-11       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.